Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Cancer Research

• Publication date

  2013-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-13-0799PMID 23948975PMCID PMC3813597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.

  2013cited by this paper
• TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer

  2012cited by this paper
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper
• Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement

  2011influential reference
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011influential reference
• A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

  2011cited by this paper
• Genomic index of sensitivity to endocrine therapy for breast cancer.

  2010cited by this paper
• Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

  2010cited by this paper
• Predicting protein-protein interactions in Arabidopsis thaliana through integration of orthology, gene ontology and co-expression

  2009cited by this paper
• Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

  2007cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

  2007cited by this paper
• Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

  2007influential reference
• Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

  2007cited by this paper
• Molecular classification of breast cancer: limitations and potential.

  2006cited by this paper
• Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

  2006cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• Summaries of Affymetrix GeneChip probe level data.

  2003cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper

• The impacts of androgen receptor on treatment response and survival in triple-negative breast cancer treated with neoadjuvant chemotherapy: a single-center retrospective study.

  2026cites this paper
• A single-cell atlas linking intratumoral states to therapeutic vulnerabilities across cancers

  2026cites this paper
• Comparative Transcriptomic Analysis Identifies Predictive Biomarkers of Pathological Complete Response in Triple-negative Breast Cancer

  2026cites this paper
• FOXM1 Signaling Network Transcriptionally Upregulates Expression of Proteins Involved in Mitotic Progression to Induce High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast Cancer.

  2026cites this paper
• The Molecular Landscape and Utility of Multiomic Analyses in Triple-Negative Breast Cancer: Further Subtyping and Exploring Novel Biomarkers and Therapeutic Targets

  2025cites this paper
• Surrogate molecular classification of LAR breast cancer in routine workflow.

  2025cites this paper
• A review on integrated design and application of stimuli-responsive ZIF-8 metal-organic frameworks for breast cancer theranostics

  2025cites this paper
• Predictors of Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer

  2025cites this paper
• The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast Tumours

  2025cites this paper
• Esophageal adenocarcinoma relapse after chemoradiation is dominated by a basal-like subtype

  2025cites this paper
• Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?

  2025cites this paper
• Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer.

  2025cites this paper
• Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00

  2025cites this paper
• Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)

  2025cites this paper
• Issues and missed opportunities in lymph node assessment after neoadjuvant chemotherapy

  2025cites this paper
• Profile of Triple Negative Breast Cancer: A Retrospective Review

  2025cites this paper
• TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses

  2025cites this paper
• Caveolin-1: an ambiguous entity in breast cancer

  2025cites this paper
• Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial

  2025cites this paper
• Case Report: Androgen receptor-positive, locoregionally advanced breast cancer in a transgender man and an update on breast cancer management in a gender-diverse patient population

  2025cites this paper
• The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer.

  2025cites this paper
• Novel Combination therapy of Osimertinib and Tupichinol E in Triple-Negative Breast Cancer: Targeting EGFR and CDK4/6 Pathways

  2025cites this paper
• PAM50 Intrinsic Subtypes and Immunity Status in Prognosis of Triple-Negative Breast Cancer: A Retrospective Cohort Study

  2025cites this paper
• Discovery of a novel BCL-2 inhibitor GW806742X for the treatment of TNBC.

  2025cites this paper
• Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer

  2025cites this paper
• Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations

  2025cites this paper
• The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study

  2025cites this paper
• Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer

  2025cites this paper
• Design, synthesis, characterization and computational studies of chalcone-imines as potent anti-breast cancer agents

  2025cites this paper
• Paving the path ForwARd: Advances and challenges in androgen receptor targeting in breast cancer.

  2025cites this paper
• Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.

  2025cites this paper
• Targeting androgen receptors in patients with metastatic breast cancer.

  2025cites this paper
• Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study

  2025cites this paper
• Research progress of molecular typing and targeted therapy for triple-negative breast cancer

  2025cites this paper
• Immunogenomic diversity of triple-negative breast cancers in obese and non-obese black and white women

  2025cites this paper
• SMART: A Spatio-Molecular Atlas of Response Trajectories in Triple-Negative Breast Cancer

  2025cites this paper
• Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancer

  2025cites this paper
• Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients

  2024cites this paper
• Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast Cancer

  2024cites this paper
• Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers

  2024cites this paper
• Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes

  2024cites this paper
• Integrated Proteogenomic Analysis Reveals Distinct Potentially Actionable Therapeutic Vulnerabilities in Triple-Negative Breast Cancer Subtypes

  2024cites this paper
• Anti-Netrin-1 decorated nanoparticles combined with chemotherapy for the treatment of triple-negative breast cancer.

  2024cites this paper
• Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification

  2024cites this paper
• Cáncer de mama triple negativo, receptor de andrógeno y otros marcadores. Estrategias terapéuticas

  2024cites this paper
• S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models

  2024cites this paper
• Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study

  2024cites this paper
• Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study

  2024cites this paper
• Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.

  2024cites this paper
• The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

  2024cites this paper
• FOXM1 Transcriptionally Co-Upregulates Centrosome Amplification and Clustering Genes and Is a Biomarker for Poor Prognosis in Androgen Receptor-Low Triple-Negative Breast Cancer

  2024cites this paper
• Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”

  2024cites this paper
• Synergistic effect of bazedoxifene and abemaciclib co‑treatment in triple‑negative breast cancer cells in vitro

  2024cites this paper
• Discovery of NO Donor-Aurovertin Hybrids as Dual Ferroptosis and Apoptosis Inducers for Treating Triple Negative Breast Cancer.

  2024cites this paper
• Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer

  2024cites this paper
• The Anticancer Effects and Therapeutic Potential of Kaempferol in Triple-Negative Breast Cancer

  2024cites this paper
• Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer

  2024cites this paper
• Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy

  2024cites this paper
• Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targets

  2024cites this paper
• The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

  2024cites this paper
• Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.

  2024cites this paper
• Emerging treatment approaches for triple-negative breast cancer

  2023influential citation
• Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

  2023cites this paper
• Promotion effect of FOXCUT as a microRNA sponge for miR-24-3p on progression in triple-negative breast cancer through the p38 MAPK signaling pathway

  2023cites this paper
• Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy

  2023cites this paper
• S100A8/A9 predicts triple-negative breast cancer response to PIM kinase and PD-1/PD-L1 inhibition

  2023cites this paper
• Modeling Purchase Intentions towards Electric 2-wheeler Vehicles by customers of Delhi/NCR

  2023cites this paper
• Apocrine lesions of breast and invasive carcinoma with apocrine differentiation: a brief review

  2023cites this paper
• Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00.

  2023cites this paper
• The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer

  2023cites this paper
• Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitro

  2023cites this paper
• Non-Response of Epstein–Barr Virus-Associated Breast Cancer after Primary Chemotherapy: Report of Two Cases

  2023cites this paper
• Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?

  2023cites this paper
• Structural immunoinformatics approach for rational design of a multi-epitope vaccine against triple negative breast cancer.

  2023cites this paper
• Treatment strategy of triple negative breast cancer in young women - do we treat them differently?

  2023cites this paper
• Lipidomics-based tissue heterogeneity in specimens of luminal breast cancer revealed by clustering analysis of mass spectrometry imaging: A preliminary study

  2023cites this paper
• Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.

  2023cites this paper
• Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.

  2023cites this paper
• Assessment of androgen receptor expression in breast cancer patients using 18 F-FDG PET/CT radiomics and clinicopathological characteristics

  2023cites this paper
• Fluorouracil exacerbates alpha-crystallin B chain—mediated cell migration in triple-negative breast cancer cell lines

  2023cites this paper
• PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer

  2023cites this paper
• Co-Delivery of Paclitaxel and Regorafenib by F127/TPGS Mixed Micelles for Triple Negative Breast Cancer Treatment

  2023cites this paper
• Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network–Based Artificial Intelligence Tool

  2023cites this paper
• Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer

  2023cites this paper
• The dual-crosslinked prospective values of RAI14 for the diagnosis and chemosurveillance in triple negative breast cancer

  2023cites this paper
• Discovering the Biological Significance and Therapeutic Potential of miR-29b-3p in Triple-Negative Breast Cancer

  2023cites this paper
• AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy

  2023cites this paper
• Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy

  2023cites this paper
• Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation

  2023cites this paper
• Deciphering the gene regulatory circuitry governing chemoresistance in Triple-Negative Breast Cancer

  2023cites this paper
• The biomarkers related to immune infiltration to predict distant metastasis in breast cancer patients

  2023cites this paper
• NFYA promotes malignant behavior of triple-negative breast cancer in mice through the regulation of lipid metabolism

  2023cites this paper
• Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review

  2023cites this paper
• The use of RNA-based treatments in the field of cancer immunotherapy

  2023cites this paper
• Impact of Pathologic Complete Response on the Prognosis of Triple-Negative Breast Cancer Patients: A Cohort Study

  2023cites this paper
• Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts

  2023cites this paper
• Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer

  2023cites this paper
• HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers

  2023cites this paper
• Changing the role of pCR in breast cancer treatment - an unjustifiable interpretation of a good prognostic factor as a “factor for a good prognosis“

  2023cites this paper
• Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes

  2023cites this paper